RBC Capital Markets raised its price target on Jamieson Wellness Inc. (JWEL.TO) to $41 from $38.

Analyst Ryland Conrad maintained an Outperform rating on shares of the Canadian manufacturer and distributor of natural health products ahead of its Q4 results on February 27.

"With strong brand equity and category dominance in Canada, we believe Jamieson is well positioned to benefit from several growth tailwinds for vitamins, minerals and supplements (VMS) including an increasing focus on health and wellness among consumers globally, supportive demographics as populations age in core markets, and greater demand in emerging markets driven by a growing middle class with higher disposable incomes," Conrad said in a note to clients.

"Against this backdrop, we believe current valuation levels represent an attractive buying opportunity given solid execution, growth runways in China and the US that continue to scale, ongoing product innovation (including GLP-1 companions) and still healthy domestic consumption despite the weaker macro environment," the analyst said.

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www.mtnewswires.com/contact-us)